Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11352356 Inhibitors of plasma kallikrein and uses thereof

Patent 11352356 was granted and assigned to Takeda Pharmaceutical Company on June, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Takeda Pharmaceutical Company

0

Current Assignee

Takeda Pharmaceutical Company

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

David Edward Ehmann0

Thomas Allen Miller0

Sarah Jocelyn Fink0

Nikolaos Papaioannou0

John Mark Ellard0

Jeremy Mark Travins0

Alastair Rae0

Gerald Wayne Shipps, Jr.0

Date of Patent

June 7, 2022

0

Patent Application Number

169084970

Date Filed

June 22, 2020

0

Patent Citations

US Patent 10259803 Therapeutic inhibitory compounds

US Patent 10301284 Therapeutic inhibitory compounds

0

US Patent 10730874 Inhibitors of plasma kallikrein and uses thereof

Patent Citations Received

US Patent 12065448 Heteroaryl plasma kallikrein inhibitors

0

Patent Primary Examiner

Tracy Vivlemore

0

CPC Code

0

0

0

0

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11352356 Inhibitors of plasma kallikrein and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool